ID   ZR-75-30
AC   CVCL_1661
SY   ZR75-30; ZR7530
DR   BTO; BTO:0004915
DR   CLO; CLO_0009728
DR   EFO; EFO_0001263
DR   CLDB; cl4822
DR   CLDB; cl4823
DR   CLDB; cl4824
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-157
DR   ATCC; CRL-1504
DR   BCRC; 60056
DR   BioSample; SAMN03471856
DR   BioSample; SAMN10988534
DR   CCLE; ZR7530_BREAST
DR   CCRID; 3111C0001CCC000240
DR   CCRID; 3131C0001000700060
DR   CCRID; 3131C0001000700203
DR   CCRID; 3131C0001001200003
DR   CCRID; 3142C0001000000053
DR   CCTCC; GDC0054
DR   Cell_Model_Passport; SIDM00971
DR   ChEMBL-Cells; CHEMBL3308094
DR   ChEMBL-Targets; CHEMBL1075613
DR   Cosmic; 687504
DR   Cosmic; 871160
DR   Cosmic; 877444
DR   Cosmic; 894095
DR   Cosmic; 904399
DR   Cosmic; 909907
DR   Cosmic; 921977
DR   Cosmic; 949194
DR   Cosmic; 979716
DR   Cosmic; 1046953
DR   Cosmic; 1047719
DR   Cosmic; 1136346
DR   Cosmic; 1152523
DR   Cosmic; 1287913
DR   Cosmic; 1289422
DR   Cosmic; 1571790
DR   Cosmic; 1603230
DR   Cosmic; 2165016
DR   Cosmic-CLP; 909907
DR   DepMap; ACH-000828
DR   ECACC; 88113004
DR   GDSC; 909907
DR   GEO; GSM69200
DR   GEO; GSM73747
DR   GEO; GSM115121
DR   GEO; GSM217611
DR   GEO; GSM219946
DR   GEO; GSM274678
DR   GEO; GSM344379
DR   GEO; GSM344429
DR   GEO; GSM350533
DR   GEO; GSM421898
DR   GEO; GSM783957
DR   GEO; GSM847450
DR   GEO; GSM847510
DR   GEO; GSM844727
DR   GEO; GSM844726
DR   GEO; GSM887751
DR   GEO; GSM888846
DR   GEO; GSM984235
DR   GEO; GSM1053719
DR   GEO; GSM1172909
DR   GEO; GSM1173005
DR   GEO; GSM1238138
DR   GEO; GSM1401666
DR   GEO; GSM1661991
DR   GEO; GSM1670589
DR   IARC_TP53; 21112
DR   LiGeA; CCLE_237
DR   LINCS_HMS; 50575
DR   LINCS_LDP; LCL-1322
DR   PharmacoDB; ZR7530_1690_2019
DR   Wikidata; Q54996119
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=688225;
RX   PubMed=3335022;
RX   PubMed=11044355;
RX   PubMed=11414198;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=20070913;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23151021;
RX   PubMed=23260012;
RX   PubMed=23601657;
RX   PubMed=24009699;
RX   PubMed=24094812;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=23260012;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
WW   http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/ZR-75-30.html
WW   http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=240
WW   http://www.cellresource.cn/fdetail.aspx?id=628
WW   http://www.cellresource.cn/fdetail.aspx?id=821
WW   http://www.cellresource.cn/fdetail.aspx?id=1584
WW   http://www.cellresource.cn/fdetail.aspx?id=2096
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Doubling time: 110 hours, at 17th passage (PubMed=688225); 60 hours (PubMed=25984343); 324.46 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: A*23:01,03:01; B*07:02,35:08; C*04:01,07:02; DQB1*06:04,06:04 (PubMed=25960936).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: APPBP2-PHF20L1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: BCAS3-HOXB9 gene fusion (PubMed=23260012).
CC   Sequence variation: COL14A1-SKAP1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: DDX5-DEPTOR in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: ERBB2-BCAS3 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: PLEC1-ENPP2 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: TAOK1-PCGF2 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: TIAM1-NRIP1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: TIMM23-ARHGAP32 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: TRPS1-LASP1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: USP32-CCDC49 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: ZMYM4-OPRD1 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: Heterozygous for BRAF p.Ile326Thr (c.977T>C) (PubMed=19593635).
CC   Sequence variation: Homozygous for CDH1 p.Glu243Ter (c.727G>T) (PubMed=19593635).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=71.64%; Native American=0.74%; East Asian, North=3.41%; East Asian, South=0%; South Asian=0%; European, North=9.83%; European, South=14.38% (PubMed=30894373).
CC   Derived from metastatic site: Ascites.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; ECACC; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10,11
ST   D16S539: 9
ST   D18S51: 17
ST   D19S433: 13.2,14.2
ST   D21S11: 31
ST   D2S1338: 17,22
ST   D3S1358: 15,18
ST   D5S818: 12,13
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 22
ST   Penta D: 2.2,10
ST   Penta E: 5,7
ST   TH01: 8,9
ST   TPOX: 10,11
ST   vWA: 18,19
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_5612 ! ZR-75-27
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 32
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
//
RX   PubMed=688225;
RA   Engel L.W., Young N.A., Tralka T.S., Lippman M.E., O'Brien S.J.,
RA   Joyce M.J.;
RT   "Establishment and characterization of three new continuous cell lines
RT   derived from human breast carcinomas.";
RL   Cancer Res. 38:3352-3364(1978).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=11044355; DOI=10.1054/bjoc.2000.1458;
RA   Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C.,
RA   Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.;
RT   "Molecular cytogenetic analysis of breast cancer cell lines.";
RL   Br. J. Cancer 83:1309-1317(2000).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A.,
RA   Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20070913; DOI=10.1186/1471-2407-10-15;
RA   Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M.,
RA   Yamamoto S., Oka M., Hirano T., Sasaki K.;
RT   "Breast cancer cell lines carry cell line-specific genomic alterations
RT   that are distinct from aberrations in breast cancer tissues:
RT   comparison of the CGH profiles between cancer cell lines and primary
RT   cancer tissues.";
RL   BMC Cancer 10:15-15(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619-619(2012).
//
RX   PubMed=23260012; DOI=10.1186/1471-2164-13-719;
RA   Schulte I., Batty E.M., Pole J.C.M., Blood K.A., Mo S., Cooke S.L.,
RA   Ng C., Howe K.L., Chin S.-F., Brenton J.D., Caldas C., Howarth K.D.,
RA   Edwards P.A.W.;
RT   "Structural analysis of the genome of breast cancer cell line ZR-75-30
RT   identifies twelve expressed fusion genes.";
RL   BMC Genomics 13:719-719(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33-R33(2013).
//
RX   PubMed=24009699; DOI=10.1371/journal.pone.0072704;
RA   Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P.,
RA   Shi S.-L., Chen C.-Y., Li Y.;
RT   "Cell surface-specific N-glycan profiling in breast cancer.";
RL   PLoS ONE 8:E72704-E72704(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=23260012; DOI=10.1186/1471-2164-13-719;
RA   Schulte I., Batty E.M., Pole J.C.M., Blood K.A., Mo S., Cooke S.L.,
RA   Ng C., Howe K.L., Chin S.-F., Brenton J.D., Caldas C., Howarth K.D.,
RA   Edwards P.A.W.;
RT   "Structural analysis of the genome of breast cancer cell line ZR-75-30
RT   identifies twelve expressed fusion genes.";
RL   BMC Genomics 13:719-719(2012).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574-3574(2019).
//